| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 41.60 mm | 41.60 mm | 41.60 mm | 41.60 mm | 41.60 mm | 41.60 mm |
| Cash burn (monthly) | 853.67 k | (no burn) | (no burn) | (no burn) | 6.91 mm | 7.36 mm |
| Cash used (since last report) | 4.34 mm | n/a | n/a | n/a | 35.11 mm | 37.38 mm |
| Cash remaining | 37.27 mm | n/a | n/a | n/a | 6.49 mm | 4.22 mm |
| Runway (months of cash) | 43.7 | n/a | n/a | n/a | 0.9 | 0.6 |
| 13F holders | Current |
|---|---|
| Total holders | 72 |
| Opened positions | 13 |
| Closed positions | 12 |
| Increased positions | 24 |
| Reduced positions | 21 |
| 13F shares | Current |
|---|---|
| Total value | 44.60 bn |
| Total shares | 63.80 mm |
| Total puts | 4.70 k |
| Total calls | 3.70 k |
| Total put/call ratio | 1.3 |
| Largest owners | Shares | Value |
|---|---|---|
| Biotechnology Value Fund L P | 8.09 mm | $8.03 mm |
| Tang Capital Management | 7.31 mm | $7.53 bn |
| Tang Capital Partners | 6.55 mm | $10.28 mm |
| BVF | 5.23 mm | $5.39 bn |
| Vanguard | 5.16 mm | $5.32 bn |
| Prosight Management | 3.91 mm | $4.02 bn |
| Millennium Management | 3.22 mm | $3.32 bn |
| Acadian Asset Management | 3.14 mm | $3.23 mm |
| Point72 Asset Management | 2.65 mm | $2.73 bn |
| Lightstone Ventures II | 2.44 mm | $0.00 |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Feb 25 | Christopher Ogden | Common Stock | Grant | Acquire A | No | No | 0 | 57,500 | 0.00 | 209,577 |
| 4 Feb 25 | Christopher Ogden | Common Stock | Grant | Acquire A | No | No | 0 | 44,000 | 0.00 | 152,077 |
| 4 Feb 25 | Christopher Ogden | Stock Option Common Stock | Grant | Acquire A | No | No | 0.864 | 115,000 | 99.36 k | 115,000 |
| 4 Feb 25 | Christopher Ogden | Stock Option Common Stock | Grant | Acquire A | No | No | 0.864 | 225,000 | 194.40 k | 225,000 |
| 4 Feb 25 | McCarthy Sean A. | Common Stock | Grant | Acquire A | No | No | 0 | 195,000 | 0.00 | 1,032,851 |
| 4 Feb 25 | McCarthy Sean A. | Common Stock | Grant | Acquire A | No | No | 0 | 180,000 | 0.00 | 837,851 |
| 4 Feb 25 | McCarthy Sean A. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.864 | 390,000 | 336.96 k | 390,000 |
| 4 Feb 25 | McCarthy Sean A. | Stock Option Common Stock | Grant | Acquire A | No | No | 0.864 | 800,000 | 691.20 k | 800,000 |
| 4 Feb 25 | Yu-Waye Chu | Common Stock | Grant | Acquire A | No | No | 0 | 57,500 | 0.00 | 139,750 |
| 4 Feb 25 | Yu-Waye Chu | Common Stock | Grant | Acquire A | No | No | 0 | 56,000 | 0.00 | 82,250 |
